HLA class II antigens (DR, DQ LOCI) and peripheral arthritis in ankylosing spondylitis. by Sanmartí Sala, Raimon et al.
Annals of the Rheumatic Diseases, 1987; 46, 497-500
HLA class II antigens (DR, DQ loci) and peripheral
arthritis in ankylosing spondylitis
R SANMARTi,l M G ERCILLA,2 M A BRANCOS,i M C CID,2
A COLLADO,1 AND J ROTItS-QUEROL'
From the Departments of 'Rheumatology and 2Immunology, Hospital Clinico y Provincial Barcelona, Spain
SUMMARY Fifty one patients with ankylosing spondylitis (AS) were typed for HLA-A, B, C,
DR, and DO antigens. The antigen frequencies were compared with those of a normal
population and with a B27 positive control group. All but one of the patients with AS were HLA-
B27 positive. A positive linkage disequilibrium between Cwl, Cw2, DR1, and the B27 antigen
was observed. Patients with AS showed a significant increase in DQw2 antigen compared with
the B27 positive control group. No differences in antigenic frequencies were observed in patients
having peripheral arthritis and patients with only axial involvement. Seven out of nine patients
(78%) with an erosive peripheral arthritis were DR7 positive, suggesting that DR7 or genes
closely linked could be related with a more aggressive peripheral joint involvement in patients
with AS.
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Since 1973 ankylosing sponclylitis (AS) has been
known to be very strongly associated with the HLA-
B27 antigen,1 2 but no convincing relationships
between this disease and other HLA class I or class
II antigens have been demonstrated.3 4
Although axial arthritis with invariable sacro-
iliac involvement characterises the disease, many
patients have involvement of the peripheral joints
at some time during the course of their disease.5 6
The occurrence of peripheral arthritis in patients
with AS could be related to environmental factors,
absent in patients with only axial involvement, or
may reflect differences in additional genetic deter-
minants which may or may not be linked to the B27
antigen.7 To analyse the genetic susceptibility to
developing peripheral arthritis in AS a few studies
were carried out,4 8 9 but the results are discordant,
probably because different methodological criteria
were used. This study reports the class I and class II
antigen frequencies in 51 spondylitic patients, 25 of
them with peripheral involvement and a subset of
these patients having an erosive peripheral arthritis.
Patients and methods
Fifty one patients (48 male, three female) fulfilling
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the New York criteria for definite AS10 were
studied. The mean duration of the disease was 17
years (range 2-36). According to the presence of
peripheral arthropathy patients were subdivided
into two groups: group I consisted of 25 patients
with axial involvement and peripheral arthritis; their
symptoms began between the ages of 12 and 39
years (mean 24-1) and had a follow up period of
between two and 27 years (mean 14-4). Polyarticular
involvement was present in 12 patients and pauciar-
ticular in 13. In five patients the onset of AS was
before the age of 16 (juvenile AS). Peripheral
arthritis was the first symptom in 14 patients.
Erosive peripheral arthritis was present in nine
patients. Group II was made up of 26 patients that
had only axial involvement with an evolution
between 10 and 36 years (mean 19-4). In these
patients the disease began between the ages of 17
and 39 years (mean 25-5). Clinical features of both
groups are shown in Table 1.
Patients with psoriasis, Reiter's syndrome, or
inflammatory bowel disease were excluded.
Peripheral joint involvement was established if
patients had had symptoms (pain, stiffness) and
signs (swelling or effusion, restriction of move-
ments) in one or more joints for more than six weeks
observed by a physician. Patients with arthralgias
without inflammation were not included. The hip
and shoulders were considered to be axial joints.
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ankylosing but not with the B27 positive control group. This
finding indicates a linkage disequilibrium between
these three antigens and B27 (Table 2). The
roupl prevalenee of the DR7 antigen in patients with AS
involvement was similar to that in the random population (35.2%
only (n=26) versus 36%) but more frequent than in the B27
No
control group (20%), thus the increase of DR7 in
No % patients with AS involves a different pattern of
2 7-7 association than in B27 positive controls. A similar
4 15 4 pattern was observed with the DQw2 antigen, which
2 7 7 was more prevalent in spondylitic patients and in the
general population than in the B27 control group
8 30*8 (p<0001). Hence a negative linkage disequilibrium
2 7 7 between DQw2 and the B27 antigen was observed.
-
- This negative linkage disequilibrium between DR7,
-_ and mainly DQw2 and HLA-B27 was not observed
in patients with AS despite the presence of the B27




HLA-A, B, and C typing was carried out by the
comVlement dependent microlymphocytotoxicity
test' with sera recognising 63 specificities defined in
the 9th Histocompatibility Workshop.12 HLA-DR
and DQ were typed by complement dependent
microlymphocytotoxicity on nylon wool enriched
mononuclear cell populations.13 Antisera used to
type HLA-A, B, C, DR, and DQ antigens were
either obtained locally or were gifts from other
laboratories.
CONTROL GROUPS
Two control groups were used in the study. The first
consisted of 200 unrelated people as representative
of the general population and the second group
included 50 unrelated people selected from the
general population having the HLA-B27 antigen.
Both control groups and patients were ethnically
comparable and living in the same area.
STATISTICAL METHODS
Statistical analysis was by the
correction when necessary.
x2 test with Yates's
Results
HLA TYPING IN AS
All patients but one were HLA-B27 positive (98%).
Homozygosity for B27 could not be excluded in five
patients. The HLA antigens Cwl, Cw2, and DR1
were significantly increased in patients with AS
compared with the random population (p<0-001)
HLA AND PERIPHERAL ARTHRITIS IN AS
No significant differences in class I and class II
antigen distribution were observed between patients
having only axial involvement (group II) and those
with peripheral arthritis (group I) (Table 3). No
differences were found either when we analysed
separately patients with pauciarticular and poly-
articular involvement (data not shown). Of the nine
patients with erosive peripheral arthritis, seven
(77-7%) had the DR7 antigen compared with only
two (12-5%) of the 16 patients with non-erosive
peripheral arthritis (p<O-005).
Table 2 HLA class I (A, B, C loci) and class II
(DR, DQ loci) antigens in AS
HLA AS Random HLA-B27
antigen (n =SI) controls controls
(n=200) (n=50)
No %
No % No %
B27 50 98 10 5 50 100
Cwl 27* 52-9 10 5 22 44
Cw2 20* 39-2 10 5 19 38
DRI 23* 45 39 19-5 19 38
DR2 3 5-8 34 17 6 12
DR3 14 27-4 48 24 12 24
DR4 8 15-6 40 20 12 24
DR5 15 29-4 59 29-5 11 22
DR6 3 5-8 19 9-5 4 8
DR7 18 35.2 72 36 10** 20
DR8-9-10 8 15-6 10 5 4 8
DQw1 26 50-9 111 55-5 32 64
DQw2 24*** 47 98 49 8 16
DQw3 17 33-3 89 44-5 24 48
Values of DR and DQ antigen frequencies and those class I
antigens showing changes are included.
*p<O.l01 and **p<O-D5 both compared with the random controls;
***p<O-OOl compared with the B27 control group.
Table 1 Characteristics
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DR1 12 48 11 42-3
DR2 0 0 3 11.5
DR3 7 28 7 26-9
DR4 2 8 6 23
DR5 7 28 8 30-7
DR6 2 8 1 3-8
DR7 9 36 9 34-6
DR8-9-10 4 16 4 15-3
DQw1 15 60 11 42-3
DQw2 11 44 13 50
DQw3 7 28 10 38-4
No differences were seen when class I antigens were analysed.
Discussion
Because of the close link between HLA-B27 and
AS little attention has been paid to the class II
antigens in this illness. Almost all studies have
shown that the prevalence of the D or DR loci in AS
is similar to that in the normal population.3 4 1417
When we compared the antigen frequencies of
patients with AS (all but one carrying the B27
antigen) with those of a B27 positive control
population a positive linkage disequilibrium be-
tween DR1 and B27 positive antigens was observed,
which would explain the increase in DR1 in AS
observed by other groups,4 14 and suggests that this
antigen does not have any role in the disease
susceptibility. We also observed a negative linkage
disequilibrium between DR7 and B27, which has
already been reported.8 12 In contrast, the fre-
quency of DR7 in our patients is similar to that of
the general population but markedly greater than
that of the B27 positive control group.
In our study DQw2 was increased in patients with
AS compared with the B27 positive control group
(47% v 16%). We are not aware of any previous
analysis of the DQ locus in AS. The existence of a
strong negative linkage disequilibrium between B27
and DQw2 was reported during the 9th Histocompa-
tibility Workshop. 12 This unexpected increase of
DQw2 (which can be due only in part to the greater
frequency of DR7 in our patients, an antigen linked
to DQw2) could point to the existence of other
genetic markers or the presence of different haplo-
types in spondylitic patients and healthy people
having the B27 antigen. This latter hypothesis could
not be confirmed by Lochead et al,'8 but class II
antigens were not studied in their report.
M0ller et al are of the opinion that AS is a
multigenic syndrome in which the B27 antigen is not
the only genetic factor involved, even though it is
the main one.7 19 The expression of these genes in
addition to B27 could cause modifications of the
clinical course of the disease. Following on from this
theory the possibility that patients with AS having
peripheral joint involvement would be genetically
different from those having only axial involvement
has recently been suggested, though results have
shown discrepancies.4 8 9
To test whether a genetic susceptibility to develop
peripheral arthritis in the course of AS is HLA
related we selected patients with peripheral arthri-
tis, most of whom were severely affected. The group
with axial involvement only had been followed up
for more than 10 years to make sure that they were
not prone to develop peripheral arthritis, as
peripheral involvement occurs frequently in the first
10 years of the disease.20
We have not found differences in HLA antigenic
frequencies between the groups of patients with or
without peripheral arthritis. The antigens Cwl,
Cw2, and DR1 were increased in both groups
because of the linkage disequilibrium with HLA-
B27.
An increased frequency of DR4 antigen was
found by Miehle et al in AS patients with 'pure
peripheral arthritis' involving only wrist, ankle, toe,
and finger joints.9 Three patients included in our
study had this pattern of joint involvement and none
of them carried the DR4 antigen.
A similar DR7 antigen frequency was found in
patients with peripheral arthropathy and those
having only axial disease. In the group with
peripheral involvement there was a relation between
the severity of the peripheral arthritis and the DR7
antigen: seven out of the nine patients with an
erosive peripheral arthritis were DR7 positive
(77-7%). Aaron et al found an increase in the DR7
antigen in AS patients with peripheral arthritis,
though the features of arthritis were not reported.8
On the other hand, an increase of DR7 in psoriatic
arthritis is well recorded,3 4 21 but none of our
patients had psoriasis. Thus the DR7 antigen, or
genes closely linked, could be related to the de-
velopment of a more aggressive peripheral arthritis
in AS. Further studies are necessary to confirm this.
The HLA-B27 antigen is the most important
marker of AS. In view of our results we cannot
exclude the possibility that other genes in the major
histocompatibility complex may contribute to the
susceptibility and clinical heterogeneity of the dis-
ease.
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